AU2014239687B2 - Transdermal drug delivery system containing rivastigmine - Google Patents

Transdermal drug delivery system containing rivastigmine Download PDF

Info

Publication number
AU2014239687B2
AU2014239687B2 AU2014239687A AU2014239687A AU2014239687B2 AU 2014239687 B2 AU2014239687 B2 AU 2014239687B2 AU 2014239687 A AU2014239687 A AU 2014239687A AU 2014239687 A AU2014239687 A AU 2014239687A AU 2014239687 B2 AU2014239687 B2 AU 2014239687B2
Authority
AU
Australia
Prior art keywords
delivery system
drug delivery
none none
transdermal drug
rivastigmine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014239687A
Other languages
English (en)
Other versions
AU2014239687A1 (en
Inventor
Joseph Y. Mo
Je Phil Ryoo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nal Pharmaceutical Group Ltd
Original Assignee
Nal Pharmaceutical Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nal Pharmaceutical Group Ltd filed Critical Nal Pharmaceutical Group Ltd
Publication of AU2014239687A1 publication Critical patent/AU2014239687A1/en
Assigned to NAL PHARMACEUTICALS, LTD. reassignment NAL PHARMACEUTICALS, LTD. Request for Assignment Assignors: NAL PHARMACEUTICALS, LTD., RYOO, JE
Assigned to NAL PHARMACEUTICAL GROUP LIMITED reassignment NAL PHARMACEUTICAL GROUP LIMITED Request for Assignment Assignors: NAL PHARMACEUTICALS, LTD.
Application granted granted Critical
Publication of AU2014239687B2 publication Critical patent/AU2014239687B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Inorganic Chemistry (AREA)
AU2014239687A 2013-03-15 2014-03-14 Transdermal drug delivery system containing rivastigmine Ceased AU2014239687B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361799015P 2013-03-15 2013-03-15
US61/799,015 2013-03-15
PCT/US2014/027357 WO2014152454A1 (en) 2013-03-15 2014-03-14 Transdermal drug delivery system containing rivastigmine

Publications (2)

Publication Number Publication Date
AU2014239687A1 AU2014239687A1 (en) 2015-10-08
AU2014239687B2 true AU2014239687B2 (en) 2018-04-05

Family

ID=51528077

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014239687A Ceased AU2014239687B2 (en) 2013-03-15 2014-03-14 Transdermal drug delivery system containing rivastigmine

Country Status (10)

Country Link
US (1) US20140271866A1 (https=)
EP (1) EP2968248A4 (https=)
JP (1) JP6391664B2 (https=)
KR (1) KR20160005024A (https=)
CN (1) CN105263488A (https=)
AU (1) AU2014239687B2 (https=)
CA (1) CA2906796A1 (https=)
HK (1) HK1220109A1 (https=)
TW (1) TWI635876B (https=)
WO (1) WO2014152454A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104523656A (zh) * 2014-11-20 2015-04-22 美吉斯制药（厦门）有限公司 一种卡巴拉汀缓释透皮贴剂及其制备方法
CN105693556A (zh) * 2016-03-01 2016-06-22 巴斯特医药科技（常州）有限公司 卡巴拉汀酒石酸盐的转化方法及其产物制成的贴片
ES2769286T3 (es) 2016-12-20 2020-06-25 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina
WO2018115010A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
ES2881783T3 (es) 2017-06-26 2021-11-30 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona
US11389421B2 (en) 2017-09-05 2022-07-19 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of rivastigmine
CA3101420A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
KR102710072B1 (ko) * 2018-08-31 2024-09-24 에스케이케미칼 주식회사 장기 투여용 리바스티그민 패취
CN108926549A (zh) * 2018-09-27 2018-12-04 安徽安科余良卿药业有限公司 卡巴拉汀凝胶贴膏及其制备方法
TWI720366B (zh) 2018-11-16 2021-03-01 得生製藥股份有限公司 經皮吸收貼片
CN113616625B (zh) * 2021-08-26 2023-05-30 大连科翔科技开发有限公司 一种卡巴拉汀的长效透皮贴剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110066120A1 (en) * 2009-09-16 2011-03-17 Samyang Corporation Transdermal delivery system, method for manufacturing the same, and transdermal delivery method using the system
DE102010026903A1 (de) * 2010-07-12 2012-01-12 Amw Gmbh Transdermales therapeutisches System mit Avocadoöl oder Palmöl als Hilfsstoff

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059426A (en) * 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
KR960703956A (ko) * 1993-07-08 1996-08-31 로버트 지. 반 슌넨베르그 아크릴릭-포화 고무 하이브리드 감압 접착제
DE19918106A1 (de) * 1999-04-22 2000-10-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern
WO2001032115A1 (en) * 1999-11-04 2001-05-10 Xel Herbaceuticals Transdermal administration of huperzine
US20020192243A1 (en) * 1999-12-16 2002-12-19 Tsung-Min Hsu Transdermal and topical administration of drugs for the treatment of Alzheimer's disease using basic enhancers
US6455066B1 (en) * 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
KR20050045946A (ko) * 2002-06-25 2005-05-17 애크럭스 디디에스 피티와이 리미티드 비정질 약학적 조성물을 이용한 경피전달속도의 제어
US7516422B2 (en) * 2005-07-21 2009-04-07 International Business Machines Corporation Graphical display of hierarchical hardlinks to files in a file system
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
DE602006020063D1 (de) * 2005-12-07 2011-03-24 Univ Ramot Wirkstoffabgebende verbundkörper
WO2009158032A1 (en) * 2008-06-25 2009-12-30 Fe2, Inc. Patches and methods for the transdermal delivery of a therapeutically effective amount of iron
US8440304B2 (en) * 2008-09-16 2013-05-14 Henkel Corporation Acrylic pressure sensitive adhesive formulation and articles comprising same
JP2012236773A (ja) * 2009-12-16 2012-12-06 Goto Takeshi 抗認知症薬物の経皮吸収製剤
NZ605352A (en) * 2010-06-30 2013-10-25 Nal Pharmaceuticals Ltd Process for producing glycosaminoglycans
KR101853082B1 (ko) * 2011-03-24 2018-04-27 테이코쿠 팔마 유에스에이, 인코포레이티드 활성제층 및 활성제 변환층을 포함하는 경피 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110066120A1 (en) * 2009-09-16 2011-03-17 Samyang Corporation Transdermal delivery system, method for manufacturing the same, and transdermal delivery method using the system
DE102010026903A1 (de) * 2010-07-12 2012-01-12 Amw Gmbh Transdermales therapeutisches System mit Avocadoöl oder Palmöl als Hilfsstoff

Also Published As

Publication number Publication date
AU2014239687A1 (en) 2015-10-08
EP2968248A4 (en) 2016-08-31
HK1220109A1 (zh) 2017-04-28
TWI635876B (zh) 2018-09-21
EP2968248A1 (en) 2016-01-20
WO2014152454A1 (en) 2014-09-25
JP6391664B2 (ja) 2018-09-19
TW201505665A (zh) 2015-02-16
KR20160005024A (ko) 2016-01-13
CN105263488A (zh) 2016-01-20
US20140271866A1 (en) 2014-09-18
CA2906796A1 (en) 2014-09-25
JP2016522792A (ja) 2016-08-04

Similar Documents

Publication Publication Date Title
AU2014239687B2 (en) Transdermal drug delivery system containing rivastigmine
KR101192969B1 (ko) 도네페질을 함유하는 경피흡수제제
JP5913981B2 (ja) ドネペジル含有経皮吸収型製剤
KR101674240B1 (ko) 리바스티그민 또는 그의 유도체 투여용 경피 치료 시스템
JP6043296B2 (ja) 有効成分を投与するための経皮治療システム
JP5301190B2 (ja) 貼付剤
CN103313705B (zh) 含有利凡斯的明的经皮吸收制剂
CN102014884A (zh) 用于施用芬太尼或其类似物的透皮治疗系统
KR20140098765A (ko) 펜타닐 또는 이의 유사체를 투여하기 위한 경피 치료 시스템
JP5632577B2 (ja) 貼付剤
KR20080077404A (ko) 비소프롤롤 함유 접착 제제
US10076502B2 (en) Transdermal therapeutic system for administering rivastigmine or derivatives thereof
WO2014159748A1 (en) Transdermal drug delivery system containing donepezil
JP7402829B2 (ja) リバスチグミンを含有する経皮治療システム
KR101566817B1 (ko) 케토티펜 또는 그 염을 함유하는 경피흡수제제
OA17599A (en) Transdermal delivery system
WO2014159778A1 (en) Transdermal drug delivery system containing fentanyl

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NAL PHARMACEUTICALS, LTD.

Free format text: FORMER APPLICANT(S): RYOO, JE; NAL PHARMACEUTICALS, LTD.

PC1 Assignment before grant (sect. 113)

Owner name: NAL PHARMACEUTICAL GROUP LIMITED

Free format text: FORMER APPLICANT(S): NAL PHARMACEUTICALS, LTD.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ RYOO, JE PHIL AND MO, JOSEPH Y.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired